What is Capricor Therapeutics Inc's earnings per share (EPS)?

Capricor Therapeutics Inc (CAPR) reported diluted earnings per share of -$2.26 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Capricor Therapeutics Inc (CAPR) Financials

CAPR

FY2025 annual

Revenue $0 -100.0% YoY

Net Income -$105.0M n/m YoY

EPS (Diluted) -$2.26 n/m YoY

Free Cash Flow -$72.7M n/m YoY

Market Cap $344.8M as of Oct 23, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.4x on $246.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CAPR SEC filings page.

Capricor Therapeutics Inc (CAPR) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CAPR FY2025 2026-10-24

Capricor operates as a development-stage business: heavy research spending and external financing outweigh still-modest commercial revenue.

The cash conversion picture is unusually direct in FY2024: a net loss of $40.5M closely matched operating cash flow of -$40.0M, indicating reported losses were largely cash costs rather than mainly non-cash accounting charges.

Revenue fell 11.5% from FY2023 to FY2024 while R&D rose 37.1%, so development spending intensified despite a smaller top line. Operating margin also deteriorated by 95.5 percentage points, showing costs expanded faster than reported revenue.

Assets expanded 190.3% while liabilities fell 30.8% from FY2023 to FY2024, a balance-sheet shift consistent with equity-funded expansion rather than debt accumulation. The 7.8x current ratio indicates substantial short-term liquidity, while financing cash flow of $152.8M alongside operating cash flow of -$40.0M shows that liquidity was built through financing while operations still consumed cash.

Financial Health Signals

Financial health score not available

Capricor Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Grey Zone

2.89

Capricor Therapeutics Inc scores 2.89, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $344.8M against total liabilities of $50.2M. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Capricor Therapeutics Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing

N/A

Capricor Therapeutics Inc reported a net loss of $105.0M while operations used $69.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Capricor Therapeutics Inc reported an operating loss of $108.1M against $3.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$42.4M

YoYn/m

QoQn/m

Capricor Therapeutics Inc's EBITDA was -$42.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income

-$40.7M

YoYn/m

QoQn/m

Capricor Therapeutics Inc reported a net loss of $40.7M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

-$0.70

YoYn/m

QoQn/m

Capricor Therapeutics Inc earned -$0.70 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$35.5M

YoYn/m

QoQn/m

5Y CAGRn/m

10Y CAGRn/m

Capricor Therapeutics Inc recorded an outflow of $35.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt

$20.9M

YoY-9.9%

QoQ-80.1%

5Y CAGR-11.3%

10Y CAGR+9.0%

Capricor Therapeutics Inc held $20.9M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding

58M

YoY+27.2%

QoQ+0.4%

Capricor Therapeutics Inc had 58M shares outstanding in Q2 2026. This represents an increase of 27.2% from the same quarter a year earlier. Against the prior quarter it is up 0.4%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-16.5%

YoY+8.1pp

QoQ-4.4pp

Capricor Therapeutics Inc's quarterly ROE was -16.5% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 8.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.4 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$28.9M

YoY+30.9%

QoQ+5.4%

Capricor Therapeutics Inc invested $28.9M in research and development in Q2 2026. This represents an increase of 30.9% from the same quarter a year earlier. Against the prior quarter it is up 5.4%.

Capital Expenditures

$4.1M

YoY+1312.0%

QoQ-20.7%

5Y CAGR+66.0%

10Y CAGR+63.4%

Capricor Therapeutics Inc invested $4.1M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 1312.0% from the same quarter a year earlier. Against the prior quarter it is down 20.7%.

Share Buybacks

Not reported for Q2 2026.

CAPR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CAPR quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	$0-100.0%	$22.3M-11.5%	$25.2M+886.8%	$2.6M+941.8%	$245K-21.1%	$310K-69.1%	$1.0M-39.9%	$1.7M-37.3%	$2.7M-33.3%	$4.0M-27.5%	$5.5M+15.3%	$4.8M+851.2%	$503K+157.4%	$196K-85.6%	$1.4M
R&D Expenses	N/A	$84.5M+69.0%	$50.0M+37.1%	$36.4M+67.1%	$21.8M+60.8%	$13.6M+60.5%	$8.5M+64.5%	$5.1M-57.4%	$12.1M+12.1%	$10.8M-32.9%	$16.0M+16.6%	$13.8M+76.7%	$7.8M+49.8%	$5.2M+97.3%	$2.6M-36.3%	$4.1M
SG&A Expenses	N/A	$23.7M+59.3%	$14.9M+16.1%	$12.8M+22.8%	$10.4M+37.0%	$7.6M+37.3%	$5.5M+54.1%	$3.6M-27.1%	$4.9M+3.5%	$4.8M-3.5%	$4.9M+12.8%	$4.4M+44.9%	$3.0M+36.6%	$2.2M+61.9%	$1.4M-35.5%	$2.1M
Operating Income	N/A	-$108.1Mn/m	-$42.6Mn/m	-$24.1Mn/m	-$29.7Mn/m	-$20.9Mn/m	-$13.7Mn/m	-$7.7Mn/m	-$15.3Mn/m	-$12.9Mn/m	-$17.0Mn/m	-$12.6Mn/m	-$6.0Mn/m	-$6.9Mn/m	-$2.1Mn/m	-$4.9M
EBITDA	N/A	-$106.3Mn/m	-$41.1Mn/m	-$23.0Mn/m	-$29.2Mn/m	-$20.7Mn/m	-$13.5Mn/m	-$7.6Mn/m	-$15.2Mn/m	-$12.7Mn/m	-$16.9Mn/m	-$12.5Mn/m	-$6.0Mn/m	-$6.9Mn/m	-$2.1Mn/m	-$4.9M
Interest Expense	N/A	$3.0Mn/m	$0	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$399K+15.7%	$345K+38.6%	$249K+24.0%	$201K+244.9%	$58Kn/m	$0n/m	$0
Income Tax	N/A	$2K0.0%	$2K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Net Income	N/A	-$105.0Mn/m	-$40.5Mn/m	-$22.3Mn/m	-$29.0Mn/m	-$20.0Mn/m	-$13.7Mn/m	-$7.6Mn/m	-$15.2M-724.8%	$2.4Mn/m	-$18.8Mn/m	-$12.9Mn/m	-$6.2Mn/m	-$8.9Mn/m	-$2.1Mn/m	-$1.1M
EPS (Basic)	N/A	-$2.26n/m	-$1.15n/m	-$0.83n/m	-$1.18n/m	-$0.87n/m	-$0.88	-$2.06	-$5.17	$0.10n/m	-$1.01n/m	-$0.81n/m	-$0.53n/m	-$0.85n/m	-$0.21n/m	-$0.13
EPS (Diluted)	-$2.45	-$2.26n/m	-$1.15n/m	-$0.83n/m	-$1.18n/m	-$0.87n/m	-$0.88	-$2.06	-$0.52	$0.09n/m	-$1.01n/m	-$0.81n/m	-$0.53n/m	-$0.85n/m	-$0.21n/m	-$0.13
Diluted Shares (Avg)	N/A	46M+32.0%	35M+31.5%	27M+9.1%	25M+6.3%	23M+48.3%	16M	4M	3M	27M+44.4%	19M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$11.1M-7.9%	$2.3M-63.4%
R&D Expenses	$28.9M+30.9%	$27.4M+44.7%	N/A	$20.4M+72.4%	$22.0M+76.3%	$18.9M+70.4%	$14.6M+46.4%	$11.8M+17.7%
SG&A Expenses	$14.1M+148.3%	$9.4M+54.9%	N/A	$5.9M+71.1%	$5.7M+85.4%	$6.1M+49.0%	$4.3M+24.6%	$3.5M+14.6%
Operating Income	-$42.9Mn/m	-$36.8Mn/m	N/A	-$26.3Mn/m	-$27.7Mn/m	-$25.0Mn/m	-$7.7Mn/m	-$13.0Mn/m
EBITDA	-$42.4Mn/m	-$36.2Mn/m	N/A	-$25.8Mn/m	-$27.2Mn/m	-$24.6Mn/m	-$7.3Mn/m	-$12.6Mn/m
Income Tax	$2K0.0%	$0n/m	N/A	N/A	$2K	$0	N/A	N/A
Net Income	-$40.7Mn/m	-$33.9Mn/m	N/A	-$24.6Mn/m	-$25.9Mn/m	-$24.4Mn/m	-$7.1Mn/m	-$12.6Mn/m
EPS (Basic)	-$0.70n/m	-$0.59n/m	-$0.62n/m	-$0.54n/m	-$0.57n/m	-$0.53n/m	-$0.11-650.0%	-$0.38n/m
EPS (Diluted)	-$0.70n/m	-$0.59n/m	-$0.62n/m	-$0.54n/m	-$0.57n/m	-$0.53n/m	-$0.11-650.0%	-$0.38n/m
Diluted Shares (Avg)	58M+26.7%	57M+25.9%	N/A	46M+38.2%	46M+43.5%	46M+45.5%	N/A	33M+28.2%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

CAPR Balance Sheet

CAPR quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$355.9M+108.8%	$170.5M+190.3%	$58.7M+17.2%	$50.1M+21.2%	$41.3M+19.4%	$34.6M+211.5%	$11.1M+20.2%	$9.2M-43.2%	$16.3M-13.2%	$18.7M+16.7%	$16.1M+17.9%	$13.6M+146.2%	$5.5M+2.1%	$5.4M+295.3%	$1.4M
Current Assets	$322.9M+97.7%	$163.4M+221.3%	$50.9M+18.6%	$42.9M+17.7%	$36.4M+8.2%	$33.7M+219.4%	$10.5M+24.5%	$8.5M-46.1%	$15.7M-13.2%	$18.1M+29.4%	$14.0M+20.5%	$11.6M+215.4%	$3.7M-29.1%	$5.2M+296.3%	$1.3M
Cash & Equivalents	$287.8M+2450.3%	$11.3M-23.2%	$14.7M+53.0%	$9.6M-72.5%	$34.9M+6.8%	$32.7M+737.7%	$3.9M-8.5%	$4.3M-30.6%	$6.1M+91.6%	$3.2M-42.5%	$5.6M-30.7%	$8.0M+364.6%	$1.7M+916.7%	$170K	N/A
Short-Term Investments	$30.3M-78.4%	$140.2M+465.6%	$24.8M-22.1%	$31.8Mn/m	$0n/m	$0-100.0%	$6.0M+99.7%	$3.0M-62.5%	$8.0M-38.5%	$13.0M+62.4%	$8.0Mn/m	$0-100.0%	$326K-92.2%	$4.2M	N/A
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.9M	N/A	N/A
Total Liabilities	$50.2M+100.5%	$25.0M-30.8%	$36.1M-5.7%	$38.3M+284.5%	$10.0M+55.2%	$6.4M+50.2%	$4.3M-7.7%	$4.6M-8.2%	$5.0M-77.8%	$22.8M+33.0%	$17.1M-14.0%	$19.9M+227.4%	$6.1M+1047.6%	$529Kn/m	-$283K
Current Liabilities	$35.8M+70.4%	$21.0M-32.8%	$31.3M+32.6%	$23.6M+470.6%	$4.1M+39.1%	$3.0M+230.9%	$898K-28.5%	$1.3M-24.9%	$1.7M-65.9%	$4.9M-25.0%	$6.5M+3.6%	$6.3M+206.9%	$2.1M+288.0%	$529K-2.3%	$541K
Non-Current Liabilities	$14.3M+258.7%	$4.0M-17.9%	$4.9M-67.0%	$14.7M+152.6%	$5.8M+69.1%	$3.4M+2.1%	$3.4M0.0%	$3.4M0.0%	$3.4M-81.1%	$17.9M+68.9%	$10.6M-22.2%	$13.6M+237.9%	$4.0Mn/m	$0n/m	-$824K
Total Equity	$305.8M+110.2%	$145.5M+543.6%	$22.6M+91.8%	$11.8M-62.4%	$31.4M+11.2%	$28.2M+312.3%	$6.8M+48.2%	$4.6M-58.9%	$11.2Mn/m	-$4.0Mn/m	-$1.0Mn/m	-$6.2Mn/m	-$535K-110.9%	$4.9M+195.7%	$1.7M
Retained Earnings	-$304.9Mn/m	-$199.8Mn/m	-$159.4Mn/m	-$137.1Mn/m	-$108.1Mn/m	-$88.0Mn/m	-$74.4Mn/m	-$66.7Mn/m	-$51.5Mn/m	-$54.0Mn/m	-$35.2Mn/m	-$22.3Mn/m	-$16.1Mn/m	-$46.7Mn/m	-$44.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$368.7M+176.1%	$326.3M+112.2%	$355.9M+108.8%	$126.4M+36.0%	$133.6M+248.9%	$153.8M+211.0%	$170.5M+190.3%	$93.0M+150.2%
Current Assets	$242.1M+95.1%	$283.1M+93.6%	$322.9M+97.7%	$101.0M+17.6%	$124.1M+304.7%	$146.3M+253.2%	$163.4M+221.3%	$85.8M+190.7%
Cash & Equivalents	$20.9M-9.9%	$105.4M+266.1%	$287.8M+2450.3%	$19.5M-71.5%	$23.2M+117.4%	$28.8M+363.3%	$11.3M-23.2%	$68.4M+661.0%
Short-Term Investments	$217.0M+118.0%	$173.2M+49.3%	$30.3M-78.4%	$79.1M+374.8%	$99.6M+430.3%	$116.0M+244.1%	$140.2M+465.6%	$16.7M-14.8%
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Total Liabilities	$122.5M+328.5%	$47.6M+82.2%	$50.2M+100.5%	$42.6M+72.4%	$28.6M+6.8%	$26.1M-15.8%	$25.0M-30.8%	$24.7M-36.6%
Current Liabilities	$33.0M+16.1%	$33.6M+50.6%	$35.8M+70.4%	$28.1M+37.5%	$28.4M+27.0%	$22.3M-15.3%	$21.0M-32.8%	$20.5M-37.8%
Non-Current Liabilities	$89.6M+45919.6%	$13.9M+268.5%	$14.3M+258.7%	$14.4M+242.5%	$195K-95.6%	$3.8M-18.2%	$4.0M-17.9%	$4.2M-30.0%
Total Equity	$246.2M+134.5%	$278.7M+118.3%	$305.8M+110.2%	$83.9M+22.9%	$105.0M+812.7%	$127.6M+592.4%	$145.5M+543.6%	$68.3Mn/m
Retained Earnings	-$379.6Mn/m	-$338.8Mn/m	-$304.9Mn/m	-$274.7Mn/m	-$250.1Mn/m	-$224.2Mn/m	-$199.8Mn/m	-$192.7Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

CAPR Cash Flow Statement

CAPR quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$104.0M	-$69.8Mn/m	-$40.0Mn/m	-$25.6M-620.6%	$4.9Mn/m	-$16.8Mn/m	-$10.1Mn/m	-$6.8Mn/m	-$13.9Mn/m	-$14.2Mn/m	-$14.5Mn/m	-$10.8M-1228.5%	$959Kn/m	-$6.1Mn/m	-$2.2Mn/m	-$4.6M
Depreciation & Amortization	N/A	$1.9M+32.5%	$1.4M+33.3%	$1.1M+100.5%	$533K+117.0%	$246K+70.8%	$144K-16.3%	$172K+9.1%	$158K+9.3%	$144K+14.7%	$126K+13.4%	$111K+164.6%	$42K+55.6%	$27K+32.4%	$20K+170.9%	$8K
Stock-Based Compensation	N/A	$17.2M+76.4%	$9.8M+32.1%	$7.4M+65.8%	$4.5M+50.3%	$3.0M+51.9%	$2.0M+178.6%	$701K-59.4%	$1.7M+0.9%	$1.7M-12.8%	$2.0M+24.7%	$1.6M+216.6%	$497K+88.5%	$264K-20.7%	$332K-58.8%	$806K
Capital Expenditures	$10.9M	$2.9M+148.9%	$1.2M-11.0%	$1.3M-34.4%	$2.0M+67.2%	$1.2M+118.5%	$548Kn/m	$0-100.0%	$316K+883.3%	$32K-83.2%	$192K+48.0%	$130K-20.3%	$163K+189.9%	$56K+317.9%	$13K+575.8%	$2K
Free Cash Flow	-$114.9M	-$72.7Mn/m	-$41.2Mn/m	-$26.9M-1022.7%	$2.9Mn/m	-$18.0Mn/m	-$10.6Mn/m	-$6.8Mn/m	-$14.2Mn/m	-$14.3Mn/m	-$14.6Mn/m	-$10.9M-1475.5%	$796Kn/m	-$6.2Mn/m	-$2.2Mn/m	-$4.7M
Investing Cash Flow	-$144.4M	$97.5Mn/m	-$116.2M-2374.5%	$5.1Mn/m	-$35.1Mn/m	-$1.2M-122.0%	$5.4Mn/m	-$3.0M-164.3%	$4.7M-6.2%	$5.0Mn/m	-$5.2M	N/A	N/A	N/A	$0n/m	-$2K
Financing Cash Flow	$246.0M	$248.9M+62.9%	$152.8M+497.2%	$25.6M+424.8%	$4.9M-75.9%	$20.2M-39.4%	$33.4M+263.7%	$9.2M+33.9%	$6.9M-40.8%	$11.6M-37.8%	$18.6M	N/A	N/A	N/A	$1.2M-48.4%	$2.3M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$193n/m	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$31.5Mn/m	-$29.3Mn/m	-$23.6Mn/m	-$19.7Mn/m	-$20.1Mn/m	-$6.4Mn/m	-$14.8Mn/m	-$11.6Mn/m
Depreciation & Amortization	$562K+15.5%	$535K+31.9%	$503K+33.8%	$495K+37.0%	$486K+36.2%	$405K+22.3%	$376K+22.1%	$361K+30.6%
Stock-Based Compensation	N/A	N/A	N/A	$4.0M+94.9%	$3.6M+69.4%	$5.7M+75.8%	N/A	$2.1M+19.5%
Capital Expenditures	$4.1M+1312.0%	$5.1M+471.6%	$1.7M+240.6%	$56K+510.6%	$288K+376.9%	$896K+47.2%	$489K-12.5%	$9K-96.6%
Free Cash Flow	-$35.5Mn/m	-$34.4Mn/m	-$25.2Mn/m	-$19.7Mn/m	-$20.4Mn/m	-$7.3Mn/m	-$15.3Mn/m	-$11.7Mn/m
Investing Cash Flow	-$48.8M-435.1%	-$154.6M-747.3%	$43.1Mn/m	$16.0M+695.7%	$14.5M-1.0%	$23.9Mn/m	-$123.4Mn/m	$2.0M-74.0%
Financing Cash Flow	-$4.2M-21770.4%	$1.5M+2820.6%	$248.8M+206.8%	$7K-100.0%	$20K-99.1%	$50K-97.8%	$81.1M+250.0%	$67.3M+30353.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CAPR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CAPR quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	N/A	-191.1%	-95.6%	-1163.9%	-8549.9%	-4412.6%	-769.5%	-917.0%	-482.4%	-424.6%	-228.6%	-125.7%	-1371.7%	-1074.2%	-361.7%
Net Margin	N/A	-181.7%	-88.5%	-1137.4%	-8175.9%	-4401.9%	-760.4%	-908.9%	91.2%	-470.3%	-233.0%	-129.9%	-1767.0%	-1059.5%	-84.9%
Return on Equity	-34.4%-6.5pp	-27.8%+70.8pp	-98.6%+147.6pp	-246.2%-182.4pp	-63.8%-15.4pp	-48.4%+63.3pp	-111.7%+217.4pp	-329.1%-350.8pp	21.7%	N/A	N/A	N/A	N/A	-42.3%+27.1pp	-69.4%
Return on Assets	-29.5%-5.8pp	-23.7%+14.2pp	-38.0%+20.0pp	-57.9%-9.5pp	-48.4%-9.0pp	-39.5%+29.3pp	-68.8%+95.5pp	-164.3%-179.2pp	14.9%+115.3pp	-100.3%-20.3pp	-80.0%-34.4pp	-45.6%+115.0pp	-160.6%-122.4pp	-38.2%+45.6pp	-83.8%
Current Ratio	9.01+1.2x	7.77+6.1x	1.63-0.2x	1.82-7.0x	8.82-2.5x	11.33-0.4x	11.74+5.0x	6.75-2.7x	9.40+5.7x	3.70+1.6x	2.14+0.3x	1.840.0x	1.79-8.0x	9.81+7.4x	2.42
Liabilities-to-Equity	0.160.0x	0.17-1.4x	1.60-1.7x	3.25+2.9x	0.32+0.1x	0.23-0.4x	0.62-0.4x	1.00+0.6x	0.45	N/A	N/A	N/A	N/A	0.11	N/A
Asset Turnover	0.00-0.1x	0.13-0.3x	0.43+0.4x	0.050.0x	0.010.0x	0.01-0.1x	0.09-0.1x	0.180.0x	0.160.0x	0.21-0.1x	0.340.0x	0.35+0.3x	0.09+0.1x	0.04-1.0x	0.99
FCF Margin	N/A	-184.8%	-106.9%	114.3%	-7352.3%	-3417.4%	-678.7%	-848.3%	-534.9%	-366.3%	-198.4%	16.6%	-1232.1%	-1125.4%	-343.4%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	-69.2%-58.6pp	-575.2%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	-63.9%-57.6pp	-555.2%
Return on Equity	-16.5%+8.1pp	-12.2%+6.9pp	N/A	-29.3%-10.9pp	-24.7%+71.0pp	-19.1%+34.0pp	-4.9%-1.5pp	-18.4%
Return on Assets	-11.1%+8.3pp	-10.4%+5.5pp	N/A	-19.4%-5.9pp	-19.4%+9.3pp	-15.9%+4.0pp	-4.2%-2.9pp	-13.5%+3.7pp
Current Ratio	7.35+3.0x	8.42+1.9x	9.01+1.2x	3.59-0.6x	4.37+3.0x	6.55+5.0x	7.77+6.1x	4.19+3.3x
Liabilities-to-Equity	0.50+0.2x	0.170.0x	0.160.0x	0.51+0.1x	0.27-2.1x	0.20-1.5x	0.17-1.4x	0.36
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	0.07-0.1x	0.02-0.1x
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-137.3%	-515.2%

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Capricor Therapeutics Inc CAPR	FY2025	$0	-$105.0M	N/A	$344.8M	—
Omeros Corporation OMER	FY2025	N/A	N/A	N/A	$1.2B	—
Candel Therapeutics, Inc. CADL	FY2025	N/A	-$38.2M	N/A	$614.4M	—
Foghorn Therapeutics Inc. FHTX	FY2025	$30.9M	-$74.3M	N/A	$118.8M	49/100
Alector, Inc. ALEC	FY2025	$21.0M	-$142.9M	N/A	$204.3M	50/100
Lineage Cell Therapeutics, Inc. LCTX	FY2025	$14.6M	-$63.5M	N/A	$252.9M	60/100

Where Capricor Therapeutics Inc Ranks

Frequently Asked Questions

What is Capricor Therapeutics Inc's annual revenue?

Capricor Therapeutics Inc (CAPR) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Capricor Therapeutics Inc's revenue growing?

Capricor Therapeutics Inc (CAPR) revenue declined by 100.0% year-over-year, from $22.3M to $0 in fiscal year 2025.

Is Capricor Therapeutics Inc profitable?

No, Capricor Therapeutics Inc (CAPR) reported a net loss of $105.0M in fiscal year 2025.

What is Capricor Therapeutics Inc's EBITDA?

Capricor Therapeutics Inc (CAPR) had EBITDA of -$106.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Capricor Therapeutics Inc's return on equity (ROE)?

Capricor Therapeutics Inc (CAPR) has a return on equity of -34.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Capricor Therapeutics Inc's free cash flow?

Capricor Therapeutics Inc (CAPR) recorded an outflow of $72.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Capricor Therapeutics Inc's operating cash flow?

Capricor Therapeutics Inc (CAPR) recorded an outflow of $69.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Capricor Therapeutics Inc's total assets?

Capricor Therapeutics Inc (CAPR) had $355.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Capricor Therapeutics Inc's capital expenditures?

Capricor Therapeutics Inc (CAPR) invested $2.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Capricor Therapeutics Inc spend on research and development?

Capricor Therapeutics Inc (CAPR) invested $84.5M in research and development during fiscal year 2025.

How many shares does Capricor Therapeutics Inc have outstanding?

Capricor Therapeutics Inc (CAPR) had 58M shares outstanding as of fiscal year 2025.

What is Capricor Therapeutics Inc's current ratio?

Capricor Therapeutics Inc (CAPR) had a current ratio of 9.01 as of fiscal year 2025, which is generally considered healthy.

What is Capricor Therapeutics Inc's liabilities-to-equity ratio?

Capricor Therapeutics Inc (CAPR) had a liabilities-to-equity ratio of 0.16 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

What is Capricor Therapeutics Inc's return on assets (ROA)?

Capricor Therapeutics Inc (CAPR) had a return on assets of -29.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Capricor Therapeutics Inc's P/E ratio?

Capricor Therapeutics Inc (CAPR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $344.8M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Capricor Therapeutics Inc's price-to-sales ratio?

Capricor Therapeutics Inc (CAPR) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $344.8M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Capricor Therapeutics Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Capricor Therapeutics Inc (CAPR) held $318.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $69.8M over that year. Dividing the one by the other, the reported balance equals about 55 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Capricor Therapeutics Inc's Altman Z-Score?

Capricor Therapeutics Inc (CAPR) has an Altman Z-Score of 2.89, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Capricor Therapeutics Inc's Piotroski F-Score?

Capricor Therapeutics Inc (CAPR) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Capricor Therapeutics Inc's earnings high quality?

Capricor Therapeutics Inc (CAPR) reported a net loss of $105.0M while operations used $69.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Capricor Therapeutics Inc cover its interest payments?

Capricor Therapeutics Inc (CAPR) reported an operating loss of $108.1M against $3.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.